SIRT1 and metabolic dysfunction-associated steatotic liver disease: CircLDLR/miR-667-5p/SIRT1 axis partially attenuates NAFLD through autophagy activation, suggesting that targeting circLDLR could be a promising treatment approach for NAFLD (Fig. 7).